CD79b CAR-T cell therapy
/ Shanghai Yake Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 30, 2020
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
(clinicaltrials.gov)
- P1; N=72; Not yet recruiting; Sponsor: Zhejiang University
CAR T-Cell Therapy • Clinical • New P1 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukaemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1